Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

To develop products that advance the field of cellular-based Immunotherapy, bringing new hope and treatments to those suffering from cancer.

Our vision is to create a world where diseases can be cured using cellular-based immunotherapies that can be tailored to the individual patient.

Bellicum Pharmaceuticals has been recognized by the International Council of Biotech, Won the Achievement Award at the Global Institute For Cell and Gene Therapy, 2019 and was listed in the Top Companies Leading the Biotechnology Excellence Award 2018 by The Journal of Biochemistry and Genetics.